SCHEMBL2840784

SCHEMBL2840784

Cc1[nH]c(-c2cccnc2)nc1-c1cnc(C(=O)c2ccccc2)nc1

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 5/20 0.63
HPGDS O60760 3/20 0.56
KMT2A Q03164 1/20 0.46
F2 P00734 1/20 0.43
F12 P00748 1/20 0.43
HPGD P15428 1/20 0.43
FHIT P49789 1/20 0.41
PIN1 Q13526 1/20 0.41
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 2/20 0.41
LDHA P00338 1/20 0.40
EPHX2 P34913 1/20 0.40
SMPD3 Q9NY59 1/20 0.40
DHODH Q02127 1/20 0.40
LMNA P02545 1/20 0.39
POLB P06746 1/20 0.39
PKN1 Q16512 1/20 0.39
PKN2 Q16513 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2319610 0.84 HPGDS (0.79) NPY5RHPGDSKMT2AHPGDKDM4E
SCHEMBL2315343 0.83 HPGDS (0.55) NPY5RHPGDSKMT2AHPGDPIN1
SCHEMBL28402826 0.81 NPY5R (0.88) NPY5RHPGDSKMT2AHPGDKDM4E
SCHEMBL10938735 0.81 PIN1 (0.57) NPY5RKMT2AF2F12HPGD
SCHEMBL2839799 0.79 HPGDS (0.70) NPY5RHPGDS
Fr-79620 SCHEMBL7370865 0.79 NPY5R (1.00) NPY5RHPGDSKMT2AHPGDPIN1
SCHEMBL2318203 0.78 F12 (0.46) NPY5RHPGDSKMT2AF2F12
SCHEMBL2840665 0.77 NPY5R (0.75) NPY5RHPGDSKMT2AHPGDKDM4E
SCHEMBL2314072 0.77 NPY5R (0.66) NPY5RHPGDSKMT2AHPGDKDM4E
SCHEMBL2837756 0.74 HPGDS (0.63) NPY5RHPGDSKMT2AHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2350059-B1 MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES CAYMAN CHEM CO (US) 2016-03-23 EP disclosed
US-9126973-B2 Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases CAYMAN CHEMICAL COMPANY, INCORPORATED (US) 2015-09-08 US disclosed
US-20150099748-A1 MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES CAYMAN CHEMICAL COMPANY, INCORPORATED 2015-04-09 US disclosed
US-8536185-B2 Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases CAYMAN CHEMICAL COMPANY, INCORPORATED (US) 2013-09-17 US disclosed
US-8450326-B2 2013-05-28 US disclosed
US-20130079375-A1 MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES CAYMAN CHEMICAL COMPANY, INCORPORATED (US) 2013-03-28 US disclosed
US-20100075990-A1 MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES CAYMAN CHEMICAL COMPANY (US) 2010-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075990-A1 MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES HPGDS, PTGIS, PTGES NPY5R 3516/4885HPGDS 1/4885KMT2A 4181/4885
US-20130079375-A1 MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES HPGDS, PTGIS, PTGES NPY5R 3516/4885HPGDS 1/4885KMT2A 4181/4885
US-20150099748-A1 MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES HPGDS, PTGIS, PTGES NPY5R 3516/4885HPGDS 1/4885KMT2A 4181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.